
CLAIMS

1. A compound of formula (I):



(I)


wherein:

R_{1a} is H or methyl;

R_{1b} is H or F;

A is group (Aa), (Ab), (Ac) or (Ad):

wherein group (Aa) is:



(Aa);

wherein:

R_2 is H, C_{1-4}alkyl, C_{1-4}alkylene(aryl), C_{1-4}alkylene(OH), C_{1-4}alkylene(C_{3-6}cycloalkyl), C_{1-4}alkylene(4-7 membered heterocycloalkyl), C_{1-4}alkoxy, OC_{1-4}alkylene(aryl), C_{1-4}alkyleneOC_{1-4}alkyl, C_{1-4}alkyleneOC_{3-6}cycloalkyl, C_{1-4}alkyleneO(4-7 membered heterocycloalkyl), C_{1-4}alkyleneO(aryl), C_{3-6}alkynyl or C_{1-4}alkenylO(C_{3-6}alkynyl);

wherein said aryl, heterocycloalkyl and cycloalkyl are optionally substituted by 1, 2 or 3 substituents each independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, halo, CN, OH, $NR_{2a}R_{2b}$, SO_2R_{2c} and $NHSO_2R_{2c}$;

R_{2a} is selected from H and C_{1-4}alkyl;


R_{2b} is selected from H, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;

R_{2c} is selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;

each R_3 is independently halo, methyl, ethyl or n-propyl;

m is 0, 1, 2, 3 or 4;

wherein group (Ab) is:



(Ab);

wherein:

R_4 is H, C_{1-4}alkyl or C_{1-4}alkylene(aryl); wherein said aryl is optionally substituted by 1, 2 or 3 substituents each independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, halo, CN, OH, $NR_{4a}R_{4b}$, SO_2R_{4c} and $NHSO_2R_{4c}$;

R_{4a} is selected from H and C_{1-4}alkyl;

R_{4b} is selected from H, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;


R_{4c} is selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;

R_5 is H or C_{1-4}alkyl;

each R_6 is independently C_{1-4}alkyl or halo;

n is 0, 1, 2 or 3;

wherein group (Ac) is:




(Ac);

wherein:

R_7 is C_{1-4}alkyl, C_{1-4}alkylene(OH) or C_{1-4}alkyleneOC_{1-4}alkyl;

o is 1 or 2;

wherein group (Ad) is:



(Ad);

wherein:

X is a bond, O or CH_2;

each R_8 is independently halo, C_{1-4}alkyl, C_{1-4}alkoxy, OC_{1-4}haloalkyl, OC_{1-4}alkylene(C_{3-6}cycloalkyl), OC_{1-4}alkylene(4-7 membered heterocycloalkyl) or OH; wherein said heterocycloalkyl and cycloalkyl are optionally substituted by 1, 2 or 3 substituents independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, halo, CN, OH, $NR_{8a}R_{8b}$, SO_2R_{8c} and $NHSO_2R_{8c}$;

R_{8a} is selected from H and C_{1-4}alkyl;

R_{8b} is selected from H, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;

R_{8c} is selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;


each R_9 is independently halo or C_{1-4}alkyl;

p is 0, 1 or 2;

q is 0, 1, 2, 3 or 4;

wherein B is group (Ba), (Bb) or (Bc):

wherein group (Ba) is:



(Ba);

wherein:

Y is $C(R_{11})(R_{12})$, $N(R_{13})$, O or S;

each R_{10} is independently halo or C_{1-4}alkyl;

r is 0, 1, 2 or 3;

R_{11} is H or C_{1-4}alkyl;

R_{12} is H or C_{1-4}alkyl; or R_{11} and R_{12} together with the carbon atom to which they are attached form a C_{3-6}cycloalkyl;

R_{13} is H, C_{1-4}alkyl or C_{3-6}cycloalkyl;


wherein said cycloalkyl is optionally substituted by 1, 2 or 3 substituents independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, halo, CN, OH, $NR_{13a}R_{13b}$, SO_2R_{13c} and $NHSO_2R_{13c}$;

R_{13a} is selected from H and C_{1-4}alkyl;

R_{13b} is selected from H, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;

R_{13c} is selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;

wherein group (Bb) is:




(Bb);

wherein:

each R_{14} is independently halo or C_{1-4}alkyl;

s is 0, 1, 2 or 3;

wherein group (Bc) is:



(Bc);

wherein:

R_{15} is C_{1-4}alkyl, C_{1-4}alkoxy, C_{3-6}cycloalkyl, C_{1-4}haloalkyl, halo or CN; wherein said cycloalkyl is optionally substituted by 1, 2 or 3 substituents independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, halo, CN, OH, $NR_{15a}R_{15b}$, SO_2R_{15c} and $NHSO_2R_{15c}$;

R_{15a} is selected from H and C_{1-4}alkyl;

R_{15b} is selected from H, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;


R_{15c} is selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;

R_{16} is H, halo or C_{1-4}alkyl; and

D, E and F are each independently C(R_{16}); or one of D, E and F is N, and the two remaining D, E and F groups are independently C(R_{16});

or a pharmaceutically acceptable salt and/or solvate thereof.

2. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 1, which is a compound of formula (I):



(I)


wherein:

R_{1a} is H or methyl;

R_{1b} is H or F;

A is group (Aa), (Ab), (Ac) or (Ad):

wherein group (Aa) is:



(Aa);

wherein:


R_2 is H, C_{1-4}alkyl, C_{1-4}alkylene(aryl), C_{1-4}alkylene(OH), C_{1-4}alkylene(C_{3-6}cycloalkyl), C_{1-4}alkylene(4-7 membered heterocycloalkyl), C_{1-4}alkoxy, OC_{1-4}alkylene(aryl), C_{1-4}alkyleneOC_{1-4}alkyl, C_{1-4}alkyleneOC_{3-6}cycloalkyl, C_{1-4}alkyleneO(4-7 membered heterocycloalkyl), C_{1-4}alkyleneO(aryl), C_{3-6}alkynyl or C_{1-4}alkenylO(C_{3-6}alkynyl);

wherein said aryl, heterocycloalkyl and cycloalkyl may be optionally substituted by up to 3 substituents each independently selected from C_{1-4}alkyl, C_{3-6}cycloaklyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, halo and CN;

each R_3 is independently halo, methyl, ethyl or n-propyl;

m is 0, 1, 2, 3 or 4;

wherein group (Ab) is:



(Ab);

wherein:


R_4 is H, C_{1-4}alkyl or C_{1-4}alkylene(aryl); wherein said aryl may be optionally substituted by up to 3 substituents each independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, halo and CN;

R_5 is H or C_{1-4}alkyl;

each R_6 is independently C_{1-4}alkyl or halo;

n is 0, 1, 2 or 3;

wherein group (Ac) is:




(Ac);

wherein:

R_7 is C_{1-4}alkyl, C_{1-4}alkylene(OH) or C_{1-4}alkyleneOC_{1-4}alkyl;

o is 1 or 2;

wherein group (Ad) is:



(Ad);

wherein:

X is a bond, O or CH_2;

each R_8 is independently halo, C_{1-4}alkyl, C_{1-4}alkoxy or OH;


each R_9 is independently halo or C_{1-4}alkyl;

p is 0, 1 or 2;

q is 0, 1, 2, 3 or 4;

wherein B is group (Ba), (Bb) or (Bc):

wherein group (Ba) is:



(Ba);

wherein:

Y is $C(R_{11})(R_{12})$, $N(R_{13})$, O or S;

each R_{10} is independently halo or C_{1-4}alkyl;


r is 0, 1, 2 or 3;

R_{11} is H or C_{1-4}alkyl;

R_{12} is H or C_{1-4}alkyl; or R_{11} and R_{12} together with the carbon atom to which they are attached form a C_{3-6}cycloalkyl;

R_{13} is H, C_{1-4}alkyl or C_{3-6}cycloalkyl;

wherein group (Bb) is:




(Bb);

wherein:

each R_{14} is independently halo or C_{1-4}alkyl;

s is 0, 1, 2 or 3;

wherein group (Bc) is:



(Bc);


wherein:

R_{15} is C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}haloalkyl or CN;

R_{16} is H, halo or C_{1-4}alkyl; and

D, E and F are each independently C(R_{16}); or one of D, E and F is N, and the two remaining D, E and F groups are independently C(R_{16});
or a pharmaceutically acceptable salt and/or solvate thereof.

3. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 1 or 2, wherein A is group (Aa):



(Aa).


4. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 3, wherein R_2 is C_{1-4}alkyl, C_{1-4}alkylene(aryl), C_{1-4}alkylene(OH), C_{1-4}alkyleneOC_{1-4}alkyl, C_{1-4}alkyleneOC_{3-6}cycloalkyl, C_{1-4}alkyleneO(aryl), C_{1-4}alkylene(4-7 membered heterocycloalkyl), C_{1-4}alkyleneO(4-7 membered heterocycloalkyl) or C_{1-4}alkyleneO(C_{3-6}alkynyl); wherein said aryl, heterocycloalkyl and cycloalkyl may be optionally substituted by up to 3 substituents each independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, halo and CN.

5. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 4, wherein each R_3 is independently fluoro or methyl.

6. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 5, wherein m is 1 or 2.

7. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 6, wherein m is 1 and R_3 is in the 3-position; or wherein m is 1 and R_3 is in the 6-position; or wherein m is 2, one R_3 is in the 3-position, and the other R_3 is in the 6-position.

8. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 7, wherein group B is group (Bc):




(Bc).

9. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 8, wherein R_{15} is methyl, ethyl, cyclopropyl, CF_3, CN, OMe, chloro or fluoro.

10. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 8 or 9, wherein D, E and F are $C(R_{16})$, and each R_{16} is independently H, fluoro, chloro or methyl.

11. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 1, which is a compound of formula (Ia'):




(Ia')

wherein:

A is group (Aa'), group (Ab'), group (Ad') or group (Ad'');

R_{15d} is methyl, ethyl, cyclopropyl, CN, CF_3, OMe, chloro or fluoro;

wherein group (Aa') is:




(Aa')

wherein:

R_{2d} is H, methyl or CH_2OMe;

each R_{3a} is independently H, fluoro or methyl; and


wherein group (Ab') is:



wherein:

R_{4d} is methyl;

wherein group (Ad') is:




(Ad')

wherein:

R_{8d} is H, methyl, OCH_2-cyclopropyl, OCH_2-oxetanyl, OCH_2CH_2F, OMe or OEt;

each R_{9a} is independently H or fluoro;

wherein group (Ad'') is:



(Ad'')

wherein:

R_{8d} is methyl; and

each R_{9a} is independently H or fluoro;

or a pharmaceutically acceptable salt and/or solvate thereof.

12. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 1, which is selected from the group consisting of:

(E)-3-(1H-benzo[*d*][1,2,3]triazol-6-yl)-*N*-(3-fluoro-2-methylphenyl)acrylamide;

(E)-*N*-(3-fluoro-2-methylphenyl)-3-(2-oxo-2,3-dihydrobenzo[*d*]thiazol-5-yl)acrylamide;

(E)-3-(3,3-dimethyl-2-oxoindolin-6-yl)-*N*-(3-fluoro-2-methylphenyl)acrylamide;

(E)-*N*-(3-fluoro-2-methylphenyl)-3-(2'-oxospiro[cyclopropane-1,3'-indolin]-6'-yl)acrylamide;

(E)-*N*-(3-fluoro-2-methylphenyl)-3-(7-fluoro-2-oxoindolin-6-yl)acrylamide;

(E)-*N*-(3-fluoro-2-methylphenyl)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)acrylamide;

(E)-*N*-(3-fluoro-2-methylphenyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl) acrylamide;

(E)-*N*-(3-fluoro-2-methylphenyl)-3-(3-methyl-2-oxoindolin-6-yl)acrylamide;

(E)-*N*-(3-chloro-2-methylphenyl)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)acrylamide;

(E)-*N*-(3-fluoro-2-methylphenyl)-3-(2-oxoindolin-6-yl)acrylamide;

(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)acrylamide;

(E)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-*N*-(o-tolyl)acrylamide;

(E)-*N*-(2-isopropylphenyl)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)acrylamide;

(E)-*N*-(2-isopropyl-6-methylphenyl)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)acrylamide;
(E)-*N*-(5-chloro-2-isopropylphenyl)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)acrylamide;
(E)-*N*-(4,5-difluoro-2-methylphenyl)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)acrylamide;
(E)-*N*-(5-fluoro-2-methylphenyl)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)acrylamide;
(E)-*N*-(3-fluoro-2-methylphenyl)-3-(4-fluoro-2-oxoindolin-6-yl)acrylamide;
(E)-*N*-(2,6-dimethylphenyl)-3-(2-oxoindolin-6-yl)acrylamide;
(E)-*N*-(3-fluoro-2,6-dimethylphenyl)-3-(2-oxoindolin-6-yl)acrylamide;
(E)-*N*-(2-methyl-2,3-dihydro-1H-inden-1-yl)-3-(2-oxoindolin-6-yl)acrylamide;
(E)-3-(1-ethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-*N*-(3-fluoro-2-methylphenyl) acrylamide;
(E)-3-(1-cyclopropyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-*N*-(3-fluoro-2-methylphenyl) acrylamide;
(E)-N-(2,3-dihydro-1H-inden-1-yl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl) acrylamide;
(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(3-methyl-1H-indazol-6-yl)acrylamide;
(E)-3-(3-cyano-1H-indazol-6-yl)-*N*-(2,3-dihydro-1H-inden-1-yl)acrylamide;
(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(5-fluoro-1H-benzo[d][1,2,3]triazol-6-yl)acrylamide;
(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(3-(trifluoromethyl)-1H-indazol-6-yl)acrylamide;
(E)-*N*-(2,6-dimethylphenyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)acrylamide;
(E)-*N*-(3-fluoro-2,6-dimethylphenyl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)acrylamide;
(E)-*N*-(2,6-dimethylphenyl)-3-(3-methyl-1H-indazol-6-yl)acrylamide;
(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(3-ethyl-1H-indazol-6-yl)acrylamide;
(E)-3-(3-cyclopropyl-1H-indazol-6-yl)-*N*-(2,3-dihydro-1H-inden-1-yl)acrylamide;
(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(4-fluoro-3-methyl-1H-indazol-6-yl)acrylamide;
(E)-*N*-(3,5-difluoro-2,6-dimethylphenyl)-3-(2-oxoindolin-6-yl)acrylamide;
(E)-*N*-(3,4-difluoro-2,6-dimethylphenyl)-3-(2-oxoindolin-6-yl) acrylamide;
(E)-*N*-(3-fluoro-2-methylphenyl)-3-(3-methyl-1H-indazol-6-yl)acrylamide;
(E)-3-(3-methyl-1H-indazol-6-yl)-*N*-(2-methyl-2,3-dihydro-1H-inden-1-yl)acrylamide;
(E)-3-(3-methyl-1H-indazol-6-yl)-*N*-(1-methyl-1H-indazol-7-yl)acrylamide;
(E)-*N*-(5-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(3-methyl-1H-indazol-6-yl)acrylamide;
(E)-*N*-(4-fluoro-3-methylphenyl)-3-(3-methyl-1H-indazol-6-yl)acrylamide;
(E)-*N*-(3-fluoro-4-methylphenyl)-3-(3-methyl-1H-indazol-6-yl)acrylamide;
Racemic-(E)-3-(3-methyl-1H-indazol-6-yl)-*N*-((1R,2R)-2-methylcyclohexyl)acrylamide;
(E)-3-(3-cyano-1H-indazol-6-yl)-*N*-(2-methyl-2,3-dihydro-1H-inden-1-yl)acrylamide;

(E)-*N*-(2-methyl-2,3-dihydro-1H-inden-1-yl)-3-(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)acrylamide;
(E)-*N*-(2-methyl-2,3-dihydro-1H-inden-1-yl)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)acrylamide;
(Z)-2-fluoro-*N*-(3-fluoro-2-methylphenyl)-3-(2-oxoindolin-6-yl)acrylamide;
(E)-*N*-(3-chloro-2-methylphenyl)-N-methyl-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)acrylamide;
(E)-*N*-(2-methylcyclopentyl)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)acrylamide;
(E)-*N*-(3-fluoro-2-(methoxymethyl)phenyl)-3-(3-methyl-1H-indazol-6-yl)acrylamide;
(E)-3-(3-cyano-1H-indazol-6-yl)-*N*-(3-fluoro-2-methylphenyl)acrylamide;
(E)-3-(3-methyl-1H-indazol-6-yl)-*N*-(3-methylchroman-4-yl)acrylamide;
(E)-*N*-(2-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(3-methyl-1H-indazol-6-yl)acrylamide;
(E)-*N*-((1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl)-3-(3-methyl-1H-indazol-6-yl)acrylamide;
(R,E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(3-methyl-1H-indazol-6-yl)acrylamide;
(E)-*N*-(chroman-4-yl)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)acrylamide;
(E)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-*N*-(1,2,3,4-tetrahydronaphthalen-1-yl)acrylamide;
(E)-*N*-(2-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(2-oxoindolin-6-yl)acrylamide;
(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(2-oxoindolin-6-yl)acrylamide;
(E)-*N*-(3,5-difluoro-2-methylphenyl)-3-(2-oxoindolin-6-yl)acrylamide;
(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(7-fluoro-1H-benzo[d][1,2,3]triazol-6-yl)acrylamide;
(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(4-fluoro-1H-benzo[d][1,2,3]triazol-6-yl)acrylamide;
(E)-*N*-(5-chloro-2-methylphenyl)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)acrylamide;
(E)-*N*-(2-methylcyclohexyl)-3-(2-oxoindolin-6-yl)acrylamide;
(E)-3-(3-methyl-1H-indazol-6-yl)-N-(-3-methylchroman-4-yl)acrylamide;
(E)-3-(3-methyl-1H-indazol-6-yl)-N-((3R,4S)-3-methylchroman-4-yl)acrylamide;
(E)-3-(3-methyl-1H-indazol-6-yl)-N-((3S,4R)-3-methylchroman-4-yl)acrylamide;
(E)-3-(3-methyl-1H-indazol-6-yl)-N-((3R,4R)-3-methylchroman-4-yl)acrylamide;
(E)-3-(3-methyl-1H-indazol-6-yl)-N-((3S,4S)-3-methylchroman-4-yl)acrylamide;
(E)-3-(3-methyl-1H-indazol-6-yl)-N-((1S,2S)-2-(oxetan-3-ylmethoxy)-2,3-dihydro-1H-inden-1-yl)acrylamide;
(E)-N-((1S,2S)-2-(cyclopropylmethoxy)-2,3-dihydro-1H-inden-1-yl)-3-(3-methyl-1H-indazol-6-yl)acrylamide;
(E)-N-((1S,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl)-3-(3-methyl-1H-indazol-6-yl)acrylamide;
(E)-N-((1S,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-(3-methyl-1H-indazol-6-yl)acrylamide;

(E)-3-(3-cyclopropyl-1H-indazol-6-yl)-N-((1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl)acrylamide;
(E)-3-(3-methoxy-1H-indazol-6-yl)-N-((1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl)acrylamide ;
(E)-3-(3-chloro-1H-indazol-6-yl)-N-((1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl)acrylamide;
(E)-3-(3-fluoro-1H-indazol-6-yl)-N-((1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl)acrylamide; and
(E)-3-(3-cyano-1H-indazol-6-yl)-N-((1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl)acrylamide;
or a pharmaceutically acceptable salt and/or solvate of any one thereof.

13. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 12, for use as a pharmaceutical.

14. The compound or pharmaceutically acceptable salt and/or solvate thereof according to one of claims 1 to 12, for use in the manufacture of a medicament for the treatment or prophylaxis of a disease or disorder in which inhibition of mPTP provides a therapeutic or prophylactic effect.

15. Use of the compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 12, in the prophylaxis or treatment of a disease or disorder selected from degenerative or neurodegenerative diseases, disorders of the central nervous system, ischemia and re-perfusion injury, metabolic diseases, inflammatory or autoimmune diseases, diseases of aging and renal diseases, such as a degenerative or neurodegenerative disease selected from the group consisting of Parkinson's disease, dementia with Lewy Bodies, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, frontal temporal dementia, chemotherapy induced neuropathy, Huntington's disease, spinocerebellar ataxias, progressive supranuclear palsy, hereditary spastic paraplegia, Duchenne muscular dystrophy, congenital muscular dystrophy, traumatic brain injury and Friedreich's ataxia.

16. A pharmaceutical composition comprising a compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 12, or a pharmaceutically acceptable salt and/or solvate thereof, and a pharmaceutically acceptable carrier or excipient.